Women and Autoimmunity PDF Print E-mail
Tuesday, 25 October 2011 20:04
50:1, 9:1, 2:1 these are just some ratios of autoimmune disease disparities between women and men. The Society for Women’s Health Research (SWHR) hosted the Capitol Hill briefing, The War Within: Women and Autoimmunity, on Tuesday, October 11 to address these concerns. The briefing featured two panelists who spoke about autoimmune diseases in women and the efforts needed to advance the understanding and treatment of these often serious conditions.

While autoimmune diseases affect both men and women, many diseases are more prevalent in women. Hashimoto’s thyroiditis, for example, which impairs functioning of the thyroid, affects 50 times more women than it does men and systemic lupus affects nine times more women than men.

Both a patient and an advocate, Kathleen Ann Arnsten has been diagnosed with eight different autoimmune diseases and must take 30 medications daily in order to function. She describes her experiences with autoimmune diseases as “devastating,” and warns that even though patients may appear healthy, pain is ravaging them within; we cannot be apathetic towards research for better treatments.

Due to the various symptoms of an autoimmune disease and the fluctuating severity of those symptoms, care is highly individualized according to the patient’s needs. Often, a patient must try many different treatments before an effective one is found. Some autoimmune diseases, like lupus, are incurable and can be fatal.

Additionally, there is a great shortage of treatments available, causing many patients to turn to expensive off-label drugs to manage their conditions. Arnsten stressed the need for further research and clinical trials surrounding autoimmune diseases, with the potential to discover and patent new treatments.

Panelist Annette Rothermel, PhD, Program Officer at the Autoimmunity and Mucosal Immunology Branch at the National Institutes of Allergy and Infectious Diseases (NIAID), spoke about NIAID and its ongoing autoimmunity research efforts. The National Institutes of Health (NIH) Autoimmune Disease Coordinating Committee, chaired by NIAID and founded in 1998, promotes research of autoimmune diseases by NIH, federal agencies, advocacy groups, and private organizations.

Current autoimmunity research funded by NIAID aims for greater understanding of the role of immune systems in initiating and maintaining autoimmune disease, improvement of experimental systems and diagnostics, and development of advanced therapies and prevention strategies for autoimmune conditions.

The fact that most patients suffer for five to 10 years from an autoimmune disease before receiving an accurate diagnosis supports the conclusion that the general public, and even healthcare professionals, remain largely unaware of autoimmune disease symptoms and the severity of such conditions. While the cure for autoimmune diseases may still be out of reach, Arnsten and Rothermel agree that large improvements can and must be made in diagnosis and treatment.

Source: SWHR (2011), "THE WAR WITHIN: WOMEN AND AUTOIMMUNITY"; Full article can be viewed here.
 
More articles :

» Health: It's About Changing Your State Of Mind

I read an interesting article by Jason Luban, a licensed acupuncturist, on why so many patients flock to alternative practitioners. Mr. Luban brought up an interesting question, “What is health?”Is health simply the absence of disease?  If...

» Rituximab Shows Promise in Scleroderma

Rituximab (Rituxan) improved lung function in patients with , a small proof-of-principle study found.At one year, patients randomized to receive rituximab had a median 10.25% increase in forced vital capacity (FVC) compared with baseline, while...

» Frequency of Sexual Dysfunction In Women With Rheumatic Diseases

Sexuality is part of human life and of quality of life, accounting for individual well-being. It relates not only to sexual intercourse itself, but also to a whole spectrum that ranges from self-image and self-valuing to relationship with the...

» Leeds Study Could Help Treat Potentially Fatal Condition

A trial of special insoles is being masterminded by Leeds-based researchers to see if they can help sufferers of a potentially fatal tissue disorder. Patients with , a rare but serious connective disorder which leads to the thickening of body...

» arGentis Expands Scientific Advisory Board

is a diversified biopharmaceutical development company located in Memphis, Tennessee. The company’s pipeline consists of mid- and late-stage platform technologies in both autoimmunity and ophthalmology. According to , the company announced...

» Targeted Therapy for Systemic Sclerosis: How Close are We?

Manuel Ramos-Casals; Vicent Fonollosa-Pla; Pilar Brito-Zerón; Antoni Sisó-AlmirallPosted: 09/14/2010; Nat Rev Rheumatol. 2010;6(5):269-278. © 2010 Nature Publishing GroupDespite recent etiopathogenetic advances, systemic sclerosis continues to be...